<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00032162</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069262</org_study_id>
    <secondary_id>AGOSG-AGO-GYN-2</secondary_id>
    <secondary_id>EU-20147</secondary_id>
    <nct_id>NCT00032162</nct_id>
  </id_info>
  <brief_title>Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer</brief_title>
  <official_title>Phase I/II Trial, Dose Finding Combination Chemotherapy With PegLiposomal Doxorubicin (PLD) And Carboplatin In Patients With Gynecologic Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGO Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AGO Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells.

      PURPOSE: Phase I/II trial to study the effectiveness of combining liposomal doxorubicin with
      carboplatin in treating patients who have gynecologic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the maximum tolerated dose of doxorubicin HCl liposome when administered with
           carboplatin in patients with gynecological tumors.

        -  Determine the dose-limiting toxicity of this regimen in these patients.

        -  Determine the kind, frequency, severity, and duration of adverse events in patients
           treated with this regimen.

      OUTLINE: This is a multicenter, dose-escalation study of doxorubicin HCl liposome.

      Patients receive doxorubicin HCl liposome IV over 60 minutes followed by carboplatin IV over
      30 minutes on day 1. Treatment repeats every 28 days for 6 courses.

      Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at
      which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is
      determined, additional patients are accrued and treated at the MTD as above.

      Patients are followed at 4-6 weeks and then every 3 months thereafter.

      PROJECTED ACCRUAL: A total of 12-24 patients will be accrued for this study within 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DL DLT</measure>
    <time_frame>DLT during first 3 cycles</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>PLD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose finding study of PLD in combination with Carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>AUC 6 q4w</description>
    <arm_group_label>PLD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated liposomal doxorubicin hydrochloride</intervention_name>
    <description>20/30/40 mg/qm q4w Dose finding study</description>
    <arm_group_label>PLD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed fallopian tube cancer, Muellerian mixed
             tumor, endometrial cancer, uterine sarcoma, ovarian cancer with sarcoma parts, or
             cervical cancer

               -  No ovarian epithelial cancer

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  ECOG 0-2 OR

          -  Karnofsky 70-100%

        Life expectancy:

          -  At least 3 months

        Hematopoietic:

          -  Absolute neutrophil count at least 1,500/mm3

          -  Platelet count at least 100,000/mm3

          -  Hemoglobin greater than 10.0 g/dL

        Hepatic:

          -  Bilirubin no greater than 1.25 times upper limit of normal

        Renal:

          -  Glomerular filtration rate at least 60 mL/min

        Cardiovascular:

          -  No atrial or ventricular arrhythmias

          -  No congestive heart failure even if stabilized on medication

          -  No New York Heart Association class III or IV heart disease

          -  No myocardial infarction within the past 6 months

        Other:

          -  No pre-existing sensory or motor neuropathy grade 2 or greater

          -  No active infection

          -  No other serious medical condition that would preclude study

          -  Not pregnant

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  At least 4 weeks since prior immunotherapy

        Chemotherapy:

          -  No more than 1 prior chemotherapy regimen for the malignancy

          -  No other concurrent chemotherapy

        Endocrine therapy:

          -  Prior hormonal therapy within the past 10 days allowed

          -  No concurrent hormonal therapy

        Radiotherapy:

          -  At least 6 weeks since prior radiotherapy to no more than 25% of bone marrow

        Surgery:

          -  Not specified

        Other:

          -  At least 30 days since prior experimental agents

          -  No other concurrent therapies that would preclude study

          -  No concurrent participation in another study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas du Bois, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Dr. Horst-Schmidt-Kliniken</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitaetsklinikum Charite</name>
      <address>
        <city>Berlin</city>
        <zip>D-10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralkrankenhaus</name>
      <address>
        <city>Bremen</city>
        <zip>D-28205</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik I</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <zip>D-40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus</name>
      <address>
        <city>Dusseldorf</city>
        <zip>DOH-40217</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Krankenhaus FFM-Hoechst</name>
      <address>
        <city>Frankfurt Am Main</city>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W. Goethe Universitaet</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Goettingen</name>
      <address>
        <city>Gottingen</city>
        <zip>D-37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Fuer Innere Medizin Hematology/Oncology, Ernst Moritz Armdt Universitaet</name>
      <address>
        <city>Greifswald</city>
        <zip>D-17487</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenklinik der MHH</name>
      <address>
        <city>Hannover</city>
        <zip>30659</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vincentius Krankenhaus</name>
      <address>
        <city>Karlsruhe</city>
        <zip>D-76137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian-Albrechts University of Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>D-24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik der Otto - v. - Guericke - Universitat</name>
      <address>
        <city>Magdeburg</city>
        <zip>39108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik fuer Kinderheilkunde</name>
      <address>
        <city>Muenster</city>
        <zip>D-48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Grosshadern</name>
      <address>
        <city>Munich (Muenchen)</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts Der Isar/Technische Universitaet Muenchen</name>
      <address>
        <city>Munich (Muenchen)</city>
        <zip>D-81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaet Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>D-89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Hors t- Schmidt - Kliniken</name>
      <address>
        <city>Wiesbaden</city>
        <zip>D-65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>du Bois A, Pfisterer J, Burchardi N, Loibl S, Huober J, Wimberger P, Burges A, Stähle A, Jackisch C, Kölbl H; Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom; Kommission Uterus. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecol Oncol. 2007 Dec;107(3):518-25. Epub 2007 Oct 25.</citation>
    <PMID>17910981</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 29, 2012</last_update_submitted>
  <last_update_submitted_qc>May 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III cervical cancer</keyword>
  <keyword>recurrent cervical cancer</keyword>
  <keyword>stage IB cervical cancer</keyword>
  <keyword>stage IIB cervical cancer</keyword>
  <keyword>stage IVB cervical cancer</keyword>
  <keyword>stage IA cervical cancer</keyword>
  <keyword>stage IIA cervical cancer</keyword>
  <keyword>stage IVA cervical cancer</keyword>
  <keyword>stage I endometrial carcinoma</keyword>
  <keyword>stage II endometrial carcinoma</keyword>
  <keyword>stage III endometrial carcinoma</keyword>
  <keyword>stage IV endometrial carcinoma</keyword>
  <keyword>recurrent endometrial carcinoma</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>stage I uterine sarcoma</keyword>
  <keyword>stage II uterine sarcoma</keyword>
  <keyword>stage III uterine sarcoma</keyword>
  <keyword>stage IV uterine sarcoma</keyword>
  <keyword>recurrent uterine sarcoma</keyword>
  <keyword>ovarian sarcoma</keyword>
  <keyword>ovarian carcinosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

